62 trials changed in the last 30 days: 4 stopped, 9 with notable changes, 49 with minor changes only.
Trial terminated
Also in this update: Final enrollment: 7 participants — 2% of the 325 planned
SanofiPhase 2 NCT07222189 Registry history of NCT07222189 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Final enrollment: 170 participants (planned 204)
SanofiPhase 2 NCT06867094 Registry history of NCT06867094 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Final enrollment: 105 participants (planned 260)
SanofiPhase 2 NCT06637631 Registry history of NCT06637631 on ClinicalTrials.gov (opens the registry)
Trial terminated
SanofiPhase 2 NCT06033833 Registry history of NCT06033833 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
And 1 more change in the last 30 days
SanofiPhase 1/2 NCT07734649 Registry history of NCT07734649 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 25, 2026 to Jun 30, 2027
SanofiNot applicable NCT07038473 Registry history of NCT07038473 on ClinicalTrials.gov (opens the registry)
Phase changed: Phase 4 → Phase 3
And 1 more change in the last 30 days
SanofiPhase 3 NCT07286214 Registry history of NCT07286214 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Oct 9, 2026 to Sep 22, 2026
SanofiPhase 1 NCT07853131 Registry history of NCT07853131 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 15 locations
SanofiNot specified NCT07282795 Registry history of NCT07282795 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 20 locations; Start date changed from estimate of Oct 2, 2026 to Oct 1, 2026
SanofiPhase 4 NCT07861542 Registry history of NCT07861542 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 15, 2026
SanofiPhase 3 NCT04701983 Registry history of NCT04701983 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 9, 2026
SanofiPhase 3 NCT04751487 Registry history of NCT04751487 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 7, 2026
SanofiPhase 2 NCT06280391 Registry history of NCT06280391 on ClinicalTrials.gov (opens the registry)
Trial status changed: Recruiting → Enrolling by Invitation
Also in this update: Trial sites expanded: 3 → 8 locations
SanofiPhase 3 NCT07793409 Registry history of NCT07793409 on ClinicalTrials.gov (opens the registry)
Trial completed
SanofiPhase 3 NCT07135986 Registry history of NCT07135986 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
SanofiPhase 1 NCT07855250 Registry history of NCT07855250 on ClinicalTrials.gov (opens the registry)
Trial completed
Principia Biopharma, a Sanofi CompanyPhase 3 NCT04562766 Registry history of NCT04562766 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Nov 5, 2026 to Sep 14, 2026
Genzyme, a Sanofi CompanyPhase 3 NCT03754790 Registry history of NCT03754790 on ClinicalTrials.gov (opens the registry)
Trial completed
SanofiNot specified NCT07615192 Registry history of NCT07615192 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
SanofiPhase 2 NCT06975722 Registry history of NCT06975722 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 23 participants (planned 20)
SanofiPhase 4 NCT05757713 Registry history of NCT05757713 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 4878935 participants (planned 533000)
SanofiNot specified NCT07094373 Registry history of NCT07094373 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 8, 2026 to Nov 28, 2026
SanofiPhase 3 NCT07103148 Registry history of NCT07103148 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 110 participants (planned 100)
SanofiNot specified NCT05991323 Registry history of NCT05991323 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
SanofiNot specified NCT06837454 Registry history of NCT06837454 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 79 participants (planned 100)
SanofiNot specified NCT06684314 Registry history of NCT06684314 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 572 participants (planned 900)
SanofiNot specified NCT06039241 Registry history of NCT06039241 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 25, 2026 to Feb 11, 2027
Also in this update: Trial sites expanded: 15 → 24 locations; Study completion pushed from Sep 23, 2026 to Mar 11, 2027
SanofiPhase 2 NCT06984627 Registry history of NCT06984627 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 10, 2026 to Nov 6, 2026
SanofiNot specified NCT06052800 Registry history of NCT06052800 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 219 → 240 locations
SanofiPhase 3 NCT07184996 Registry history of NCT07184996 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 432 → 461 locations
SanofiPhase 3 NCT07184931 Registry history of NCT07184931 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 90 → 109 locations
SanofiPhase 3 NCT07184944 Registry history of NCT07184944 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 20 locations
SanofiPhase 2 NCT07688213 Registry history of NCT07688213 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 92 → 95 locations
SanofiPhase 3 NCT07190196 Registry history of NCT07190196 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 99 → 105 locations
SanofiPhase 3 NCT07086976 Registry history of NCT07086976 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 4 → 8 locations
SanofiPhase 3 NCT07710872 Registry history of NCT07710872 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 30 → 41 locations
SanofiPhase 3 NCT07285460 Registry history of NCT07285460 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 294 → 314 locations
SanofiPhase 3 NCT07190209 Registry history of NCT07190209 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 32 → 35 locations
SanofiPhase 1/2 NCT07215234 Registry history of NCT07215234 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 82 → 85 locations
SanofiPhase 4 NCT07053423 Registry history of NCT07053423 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 16 → 21 locations
SanofiPhase 2 NCT07810010 Registry history of NCT07810010 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 75 → 79 locations
SanofiPhase 2 NCT06500702 Registry history of NCT06500702 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 37 → 40 locations
SanofiPhase 2 NCT02991469 Registry history of NCT02991469 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 55 → 171 locations
SanofiPhase 3 NCT07185009 Registry history of NCT07185009 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 53 → 63 locations
SanofiPhase 3 NCT06975865 Registry history of NCT06975865 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 83 → 86 locations
SanofiPhase 2 NCT07225569 Registry history of NCT07225569 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 197 → 202 locations
SanofiPhase 3 NCT07088068 Registry history of NCT07088068 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 63 → 73 locations
SanofiPhase 2/3 NCT07412470 Registry history of NCT07412470 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 58 → 50 locations
SanofiPhase 3 NCT05206773 Registry history of NCT05206773 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 23 → 46 locations
SanofiPhase 3 NCT07424144 Registry history of NCT07424144 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 40 → 68 locations
SanofiPhase 3 NCT07325292 Registry history of NCT07325292 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 150 → 154 locations
SanofiPhase 3 NCT06241118 Registry history of NCT06241118 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 79 → 85 locations
SanofiPhase 2 NCT07170917 Registry history of NCT07170917 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 4 → 12 locations
SanofiPhase 1/2 NCT07704580 Registry history of NCT07704580 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 19 → 25 locations
SanofiPhase 3 NCT07348692 Registry history of NCT07348692 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 214 → 315 locations
SanofiPhase 3 NCT07190222 Registry history of NCT07190222 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 3 → 7 locations
SanofiNot specified NCT07612878 Registry history of NCT07612878 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Sep 16, 2027 to Mar 26, 2027
SanofiPhase 3 NCT06834347 Registry history of NCT06834347 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Oct 11, 2027 to Feb 17, 2027
Also in this update: Primary completion date changed from estimate of Nov 6, 2026 to Sep 24, 2026
SanofiPhase 3 NCT06834360 Registry history of NCT06834360 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 62 → 71 locations
SanofiNot specified NCT07556159 Registry history of NCT07556159 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 79 → 82 locations
SanofiNot specified NCT07290803 Registry history of NCT07290803 on ClinicalTrials.gov (opens the registry)
Interventions modified
SanofiPhase 2 NCT06958536 Registry history of NCT06958536 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-22 | NCT07890454 Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza… | Phase 3 | Not Yet Recruiting |
| 2026-10-06 | NCT07861542 Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at… | Phase 4 | Recruiting |
| 2026-10-02 | NCT07855250 An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1… | Phase 1 | Active, Not Recruiting |
| 2026-10-01 | NCT07853131 Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult… | Phase 1 | Recruiting |
| Phase 1 | 11 | |
| Phase 1/2 | 15 | |
| Phase 2 | 38 | |
| Phase 2/3 | 2 | |
| Phase 3 | 52 | |
| Phase 4 | 12 |
Atopic Dermatitis (14) · Diabetes (11) · Type 1 Diabetes (10) · COPD (8) · Multiple Myeloma (8) · Hemophilia (6) · Asthma (5) · Multiple Sclerosis (5) · Ulcerative Colitis (5) · Hidradenitis Suppurativa (4)